| Sinusitis (acute): antimicrobial prescribing | NG79 | | |
| Cataracts in adults: management | NG77 | | |
| Cystic fibrosis: diagnosis and management | NG78 | | |
| Hepatitis B (chronic): diagnosis and management | CG165 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Child maltreatment: when to suspect maltreatment in under 18s | CG89 | | |
| Child abuse and neglect | NG76 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| Faltering growth: recognition and management of faltering growth in children | NG75 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Intermediate care including reablement | NG74 | | |
| Type 2 diabetes: prevention in people at high risk | PH38 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Fertility problems: assessment and treatment | CG156 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Psoriasis: assessment and management | CG153 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Vitamin D: supplement use in specific population groups | PH56 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Developmental follow-up of children and young people born preterm | NG72 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment | MTG2 | | |
| Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Parkinson's disease in adults | NG71 | | |
| Constipation in children and young people: diagnosis and management | CG99 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners | DG3 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| Air pollution: outdoor air quality and health | NG70 | | |
| Eliglustat for treating type 1 Gaucher disease | HST5 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis | DG29 | | |
| Obesity: working with local communities | PH42 | | |
| Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
| Virtual chromoendoscopy to assess colorectal polyps during colonoscopy | DG28 | | |
| Intravenous fluid therapy in adults in hospital | CG174 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
| Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
| Sexually transmitted infections: condom distribution schemes | NG68 | | |
| Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
| Managing medicines for adults receiving social care in the community | NG67 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Patient group directions | MPG2 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Mental health of adults in contact with the criminal justice system | NG66 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Ustekinumab for the treatment of adults with moderate to severe psoriasis | TA180 | | |
| Molecular testing strategies for Lynch syndrome in people with colorectal cancer | DG27 | | |
| Migalastat for treating Fabry disease | HST4 | | |
| Drug misuse prevention: targeted interventions | NG64 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
| HumiGard for preventing inadvertent perioperative hypothermia | MTG31 | | |
| Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
| Cerebral palsy in under 25s: assessment and management | NG62 | | |
| Antimicrobial stewardship: changing risk-related behaviours in the general population | NG63 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Hypothermia: prevention and management in adults having surgery | CG65 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| XprESS multi sinus dilation system for treating chronic sinusitis | MTG30 | | |
| HIV testing: increasing uptake among people who may have undiagnosed HIV | NG60 | | |
| Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
| Coexisting severe mental illness and substance misuse: community health and social care services | NG58 | | |
| Spasticity in under 19s: management | CG145 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| High-throughput non-invasive prenatal testing for fetal RHD genotype | DG25 | | |
| Physical health of people in prison | NG57 | | |
| Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | TA407 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Multimorbidity: clinical assessment and management | NG56 | | |
| Harmful sexual behaviour among children and young people | NG55 | | |
| Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
| Transition between inpatient mental health settings and community or care home settings | NG53 | | |
| Stable angina: management | CG126 | | |
| Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Palliative care for adults: strong opioids for pain relief | CG140 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation | TA398 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
| Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
| Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
| Oral health for adults in care homes | NG48 | | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
| Haematological cancers: improving outcomes | NG47 | | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
| ImmunoCAP ISAC 112 for multiplex allergen testing | DG24 | | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Controlled drugs: safe use and management | NG46 | | |
| Routine preoperative tests for elective surgery | NG45 | | |
| Workplace health: management practices | NG13 | | |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
| Community engagement: improving health and wellbeing and reducing health inequalities | NG44 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Spectra Optia for automatic red blood cell exchange in people with sickle cell disease | MTG28 | | |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
| Transition from children's to adults' services for young people using health or social care services | NG43 | | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) | DG22 | | |
| Fractures (non-complex): assessment and management | NG38 | | |
| Major trauma: assessment and initial management | NG39 | | |
| Major trauma: service delivery | NG40 | | |
| Spinal injury: assessment and initial management | NG41 | | |
| Skin cancer prevention | PH32 | | |
| Sunlight exposure: risks and benefits | NG34 | | |
| TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
| Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
| Older people: independence and mental wellbeing | NG32 | | |
| Care of dying adults in the last days of life | NG31 | | |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
| Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| Oral health promotion: general dental practice | NG30 | | |
| Transition between inpatient hospital settings and community or care home settings for adults with social care needs | NG27 | | |
| Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care | NG26 | | |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
| Vortioxetine for treating major depressive episodes | TA367 | | |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
| Blood transfusion | NG24 | | |
| VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions | DG19 | | |
| Older people with social care needs and multiple long-term conditions | NG22 | | |
| Developing and updating local formularies | MPG1 | | |
| Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
| Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset | NG16 | | |
| Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) | DG18 | | |
| Home care: delivering personal care and practical support to older people living in their own homes | NG21 | | |
| Coeliac disease: recognition, assessment and management | NG20 | | |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
| Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use | NG15 | | |
| Naloxegol for treating opioid‑induced constipation | TA345 | | |
| Aflibercept for treating diabetic macular oedema | TA346 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
| Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
| Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
| Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
| Lower urinary tract symptoms in men: management | CG97 | | |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
| Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges | NG11 | | |
| Violence and aggression: short-term management in mental health, health and community settings | NG10 | | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
| Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
| Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
| Obesity prevention | CG43 | | |
| Preventing excess weight gain | NG7 | | |
| Excess winter deaths and illness and the health risks associated with cold homes | NG6 | | |
| Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes | NG5 | | |
| VibraTip for testing vibration perception to detect diabetic peripheral neuropathy | MTG22 | | |
| Safe midwifery staffing for maternity settings | NG4 | | |
| Bladder cancer: diagnosis and management | NG2 | | |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
| Sofosbuvir for treating chronic hepatitis C | TA330 | | |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Eculizumab for treating atypical haemolytic uraemic syndrome | HST1 | | |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
| Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment | DG16 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
| The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury | MTG21 | | |
| Maternal and child nutrition | PH11 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
| Gallstone disease: diagnosis and management | CG188 | | |
| Oral health: local authorities and partners | PH55 | | |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
| Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | CG115 | | |
| Physical activity: exercise referral schemes | PH54 | | |
| Drug allergy: diagnosis and management | CG183 | | |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
| Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) | DG13 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
| Safe staffing for nursing in adult inpatient wards in acute hospitals | SG1 | | |
| The geko device for reducing the risk of venous thromboembolism | MTG19 | | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
| Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
| Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
| Weight management: lifestyle services for overweight or obese adults | PH53 | | |
| Pressure ulcers: prevention and management | CG179 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
| Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | DG12 | | |
| Contraceptive services for under 25s | PH51 | | |
| Needle and syringe programmes | PH52 | | |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| Managing medicines in care homes | SC1 | | |
| Psychosis and schizophrenia in adults: prevention and management | CG178 | | |
| Domestic violence and abuse: multi-agency working | PH50 | | |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
| Behaviour change: individual approaches | PH49 | | |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
| Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
| Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
| Weight management: lifestyle services for overweight or obese children and young people | PH47 | | |
| Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel | DG11 | | |
| EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer | DG9 | | |
| Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer | DG8 | | |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
| Varicose veins: diagnosis and management | CG168 | | |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
| Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
| Mirabegron for treating symptoms of overactive bladder | TA290 | | |
| Falls in older people: assessing risk and prevention | CG161 | | |
| Physical activity: brief advice for adults in primary care | PH44 | | |
| Social anxiety disorder: recognition, assessment and treatment | CG159 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
| Omalizumab for treating severe persistent allergic asthma | TA278 | | |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
| Antisocial personality disorder: prevention and management | CG77 | | |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
| Hepatitis B and C testing: people at risk of infection | PH43 | | |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
| Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
| Physical activity: walking and cycling | PH41 | | |
| Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
| Ivabradine for treating chronic heart failure | TA267 | | |
| Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M | DG6 | | |
| Social and emotional wellbeing: early years | PH40 | | |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
| Alteplase for treating acute ischaemic stroke | TA264 | | |
| Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
| SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver | DG5 | | |
| Mega Soft Patient Return Electrode for use during monopolar electrosurgery | MTG11 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
| Sickle cell disease: managing acute painful episodes in hospital | CG143 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
| Pharmalgen for the treatment of bee and wasp venom allergy | TA246 | | |
| Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
| Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults | TA245 | | |
| Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
| Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services | CG136 | | |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| Healthcare-associated infections: prevention and control | PH36 | | |
| The EOS 2D/3D imaging system | DG1 | | |
| Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
| Mifamurtide for the treatment of osteosarcoma | TA235 | | |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
| Ambulight PDT for the treatment of non-melanoma skin cancer | MTG6 | | |
| The MIST Therapy system for the promotion of wound healing | MTG5 | | |
| Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
| Type 2 diabetes prevention: population and community-level interventions | PH35 | | |
| Golimumab for the treatment of psoriatic arthritis | TA220 | | |
| Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | CG120 | | |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
| Food allergy in under 19s: assessment and diagnosis | CG116 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
| Sedation in under 19s: using sedation for diagnostic and therapeutic procedures | CG112 | | |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
| Prucalopride for the treatment of chronic constipation in women | TA211 | | |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
| Unintentional injuries: prevention strategies for under 15s | PH29 | | |
| Unintentional injuries in the home: interventions for under 15s | PH30 | | |
| Unintentional injuries on the road: interventions for under 15s | PH31 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
| Bedwetting in under 19s | CG111 | | |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
| Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors | CG110 | | |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
| Weight management before, during and after pregnancy | PH27 | | |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Cardiovascular disease prevention | PH25 | | |
| Alcohol-use disorders: prevention | PH24 | | |
| Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
| Improving outcomes for people with skin tumours including melanoma | CSG8 | | |
| Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
| Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
| Donor milk banks: service operation | CG93 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Depression in adults with a chronic physical health problem: recognition and management | CG91 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Guidance on the use of electroconvulsive therapy | TA59 | | |
| Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
| Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
| Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
| Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
| Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management | CG84 | | |
| Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | TA170 | | |
| Rehabilitation after critical illness in adults | CG83 | | |
| Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
| Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
| Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | CG76 | | |
| Borderline personality disorder: recognition and management | CG78 | | |
| Physical activity for children and young people | PH17 | | |
| Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
| Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
| Mental wellbeing in over 65s: occupational therapy and physical activity interventions | PH16 | | |
| Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
| Cardiovascular disease: identifying and supporting people most at risk of dying early | PH15 | | |
| Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | TA157 | | |
| Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
| Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
| Entecavir for the treatment of chronic hepatitis B | TA153 | | |
| Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
| Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Adalimumab for the treatment of adults with psoriasis | TA146 | | |
| Physical activity in the workplace | PH13 | | |
| Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over | TA138 | | |
| Structural neuroimaging in first-episode psychosis | TA136 | | |
| Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma | TA137 | | |
| Infliximab for the treatment of adults with psoriasis | TA134 | | |
| Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
| Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years | TA131 | | |
| Behaviour change: general approaches | PH6 | | |
| Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
| Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Acutely ill adults in hospital: recognising and responding to deterioration | CG50 | | |
| Drug misuse in over 16s: opioid detoxification | CG52 | | |
| Drug misuse in over 16s: psychosocial interventions | CG51 | | |
| Varenicline for smoking cessation | TA123 | | |
| Faecal incontinence in adults: management | CG49 | | |
| Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
| Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
| Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
| Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
| Naltrexone for the management of opioid dependence | TA115 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Etanercept and efalizumab for the treatment of adults with psoriasis | TA103 | | |
| Improving outcomes for people with brain and other central nervous system tumours | CSG10 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer | TA100 | | |
| Improving outcomes for people with sarcoma | CSG9 | | |
| Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
| Obsessive-compulsive disorder and body dysmorphic disorder: treatment | CG31 | | |
| Improving outcomes in children and young people with cancer | CSG7 | | |
| HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| Improving outcomes in head and neck cancers | CSG6 | | |
| Dental checks: intervals between oral health reviews | CG19 | | |
| Laparoscopic surgery for inguinal hernia repair | TA83 | | |
| Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
| Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
| Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
| Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
| Improving supportive and palliative care for adults with cancer | CSG4 | | |
| Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
| Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
| Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
| Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
| Improving outcomes in urological cancers | CSG2 | | |
| Improving outcomes in breast cancer | CSG1 | | |
| Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) | TA38 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
| Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
| Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma | TA10 | | |
| Guidance on the extraction of wisdom teeth | TA1 | | |